Novo Nordisk argues compounded semaglutide sales breach state competition laws
The company is pressing unfair competition claims against sellers of compounded versions of its peptide, extending its litigation campaign against the compounding channel.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 30 13:49 ETSource: Mealey's
The wire
- 01Novo Nordisk contends that sales of compounded semaglutide violate state unfair competition statutes, according to legal trade coverage of the filing.
- 02Compounders, telehealth prescribers and 503A pharmacies still offering semaglutide formulations face mounting legal exposure as the brand pursues state-law theories alongside federal claims.
- 03Details of the court, defendants and procedural posture were not described in the item; the outcome of the claims remains undecided.
From the source
Read at mealeys.comNovo Nordisk: Compounded Semaglutide Sales Violate State Unfair Competition Laws
